• Bullish on Biotech  Tuesday, 5 Apr 2011 | 1:34 PM ET

    Insight on why now is the right time to invest in biotech stocks, with Dr. Mark Monane, Needham & Co. biotech analyst.

  • Get Cramer's calls on the stocks home gamers asked about.

  • Valeant Seeks to Buy Cephalon for $5.7 Billion Wednesday, 30 Mar 2011 | 2:23 AM ET

    Canadian drugmaker Valeant Pharmaceuticals International said it made an unsolicited $5.7 billion bid to buy Cephalon and plans to make its case directly to Cephalon shareholders.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Market Pro: 3 Reasons the Euro Remains Strong Friday, 25 Mar 2011 | 2:18 PM ET

    Despite concerns about the European debt crisis, the euro remains strong. Rebecca Patterson of J. P. Morgan Private Bank explains why.

  • Cramer makes the call on viewers' favorite stocks.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • The "Fast" traders explain why these market movers are worth watching and how they plan to play it.

  • Halftime: Top 3 Cloud Trades for 2011 Tuesday, 14 Dec 2010 | 1:45 PM ET

    A highly regarded cloud computing analyst reveals his best plays for the new year.

  • Joe Terranova's Best Biotech Play for 2011 Thursday, 2 Dec 2010 | 6:19 PM ET

    The "Fast Money" trader thinks "biotech's the place to be" next year and here's how he suggests playing it.

  • How can investors profit from health care? Uri Landesman, president of Platinum Partners and Doug Roberts, chief investment strategist at Channel Capital Research shared their favorite plays on the sector.

  • All New Biotech Specs: Part 2 Tuesday, 12 Oct 2010 | 6:37 PM ET

    On Tuesday, Cramer highlighted the action—and potential M&A activity—in the fight to cure hepatitis C.

  • Sanofi Moves Closer to Hostile Bid for Genzyme Wednesday, 25 Aug 2010 | 3:30 PM ET
    Sanofi Aventis

    In the last two days Sanofi has hired a proxy solicitor and its bankers have become more aggressive in seeking out the opinions of Genzyme shareholders about what price they would accept in a hostile offer.

  • So far this year, the performance of the biotechnology index has been strong. So is there room for more growth in the sector? Mark Schoenebaum, managing director and senior research analyst at Deutsche Bank Securities shared his stock picks.

  • Market Trend has Turned Negative: Stock Picker Wednesday, 27 Jan 2010 | 11:53 AM ET

    We are market trend followers and we’re 100 percent in cash at the moment because the trend has turned negative, said Graham Bibby, CEO and CIO of Richmond Asset Management. He shared his investment strategy.

  • Brendan Fraser and Harrison Ford in Extraordinary Measures

    Bristol-Myers Squibb headquarters have moved from New York City to Portland, Oregon and Genzyme’s from Cambridge, Massachusetts to Seattle. Not for real, but in the movie “Extraordinary Measures” that opens today. I got to see it last night at the New York premiere.

  • Another Biotech CEO Bites The Dust Tuesday, 5 Jan 2010 | 3:18 PM ET
    James C. Mullen

    Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.

  • The Poop On Genzyme Thursday, 17 Dec 2009 | 10:32 AM ET

    I went to the beleaguered Genzyme manufacturing plant in Allston, MA yesterday to get briefed on what exactly happened/is happening there for background ahead of my interview today with the CEO.

  • 5 Best Biotech Plays Now: Analysts Monday, 28 Sep 2009 | 6:55 PM ET

    Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.

  • Markets Will Drop 7-17% in October: Strategist Friday, 25 Sep 2009 | 3:21 PM ET

    Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.